Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, et al. Ann Oncol 2024;35:429-436.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Pusztai L, Denkert C, O'Shaughnessy J, Cortes J, et al. Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522. Ann Oncol 2024;35:429-436.
PMID: 38369015